Home LiteratureArticle Details
PMID: 11070029 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Episomal segregation of the adenovirus enhancer sequence by conditional genome rearrangement abrogates late viral gene expression.

Journal of virology ·Vol. 74 ·No. 23 ·2000-12-00 ·Pages 11296-303

Wang X, Zeng W, Murakawa M, Freeman MW, Seed B

Abstract

We have constructed a recombinant adenovirus gene delivery system that is capable of undergoing growth phase-dependent site-specific recombination. When propagated in 293 producer cells, the vector retains its linear double-stranded form and can be propagated to high titer and purified by conventional procedures. Upon introduction into target cells, the viral chromosome undergoes cyclization to generate an autonomously replicating circular episome and a detached linear fragment. The viral enhancer and reporter gene segregate with the circular episome, which contains no adenovirus open reading frames. The effect of rearrangement of adenovirus gene expression was assessed by quantitative reverse transcription-PCR measurement of the abundance of transcripts encoding the tripartite leader sequence (TPL) of the major late promoter. Whereas nonrearranging viruses produced approximately 10(4) TPL transcripts per 10(6) infecting genomes in the HepG2 liver cell line, no transcripts were detectable in the same cells infected with comparable levels of circularizing vector. Because no helper virus is required to propagate these vectors, the problems of recombination with and contamination by helper virus are eliminated. We also present an efficient and reliable method for generating recombinant adenoviruses.

MeSH Terms
Adenoviridae/genetics Cells, Cultured Enhancer Elements, Genetic Gene Expression Gene Rearrangement Gene Transfer, Horizontal Genetic Vectors Herpesvirus 4, Human/genetics Humans Plasmids Polymerase Chain Reaction Recombination, Genetic
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Wang X
Nessel Gene Therapy Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
Zeng W
Murakawa M
Freeman M W
Seed B
References (51)
51 references, click to expand
  1. Characterization of an adenovirus gene transfer vector containing an E4 deletion.
    Hum Gene Ther. 1995 Oct;6(10):1343-53 PMID: 8590739
  2. Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo.
    J Virol. 1996 Dec;70(12):8944-60 PMID: 8971024
  3. Structure of the hepatic control region of the human apolipoprotein E/C-I gene locus.
    J Biol Chem. 1995 Sep 22;270(38):22577-85 PMID: 7673250
  4. High mutation frequency in DNA transfected into mammalian cells.
    Proc Natl Acad Sci U S A. 1983 May;80(10):3015-9 PMID: 6574469
  5. Activation of gene expression by adenovirus and herpesvirus regulatory genes acting in trans and by a cis-acting adenovirus enhancer element.
    Cell. 1983 Nov;35(1):127-36 PMID: 6313219
  6. Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit.
    J Virol. 1996 Jan;70(1):559-65 PMID: 8523570
  7. Selective extraction of polyoma DNA from infected mouse cell cultures.
    J Mol Biol. 1967 Jun 14;26(2):365-9 PMID: 4291934
  8. Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity.
    J Virol. 1998 Mar;72(3):2388-97 PMID: 9499099
  9. Rescue of functional replication origins from embedded configurations in a plasmid carrying the adenovirus genome.
    Mol Cell Biol. 1984 Feb;4(2):302-9 PMID: 6700592
  10. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo.
    Gene Ther. 1996 Feb;3(2):137-44 PMID: 8867861
  11. Use of the cosmid adenoviral vector cloning system for the in vitro construction of recombinant adenoviral vectors.
    Hum Gene Ther. 1997 Jul 20;8(11):1321-30 PMID: 9295127
  12. An adenovirus-Epstein-Barr virus hybrid vector that stably transforms cultured cells with high efficiency.
    J Virol. 1999 Sep;73(9):7582-9 PMID: 10438848
  13. The adenovirus type 5 E1A transcriptional control region contains a duplicated enhancer element.
    Cell. 1983 Jul;33(3):695-703 PMID: 6871991
  14. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted.
    J Virol. 1998 Feb;72(2):926-33 PMID: 9444984
  15. c-myc products trans-activate the adenovirus E4 promoter in EC stem cells by using the same target sequence as E1A products.
    J Virol. 1988 Dec;62(12):4533-7 PMID: 2972842
  16. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene.
    Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):7866-71 PMID: 9653106
  17. Manipulation of adenovirus vectors.
    Methods Mol Biol. 1991;7:109-28 PMID: 21416352
  18. Common control of the heat shock gene and early adenovirus genes: evidence for a cellular E1A-like activity.
    Mol Cell Biol. 1984 May;4(5):867-74 PMID: 6547205
  19. In vivo identification of sequence elements required for normal function of the adenovirus major late transcriptional control region.
    Nucleic Acids Res. 1986 Aug 11;14(15):6327-35 PMID: 2944077
  20. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses.
    Immunity. 1994 Aug;1(5):433-42 PMID: 7533647
  21. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal.
    Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13565-70 PMID: 8942974
  22. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells.
    Nature. 1985 Feb 28-Mar 6;313(6005):812-5 PMID: 2983224
  23. Rearrangement and mutagenesis of a shuttle vector plasmid after passage in mammalian cells.
    Proc Natl Acad Sci U S A. 1983 May;80(10):3010-4 PMID: 6304690
  24. Codon usage limitation in the expression of HIV-1 envelope glycoprotein.
    Curr Biol. 1996 Mar 1;6(3):315-24 PMID: 8805248
  25. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase.
    Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5731-6 PMID: 8650161
  26. Characterization of a replication-incompetent adenovirus type 5 mutant deleted for the preterminal protein gene.
    Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14686-91 PMID: 8962115
  27. Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy.
    J Virol. 1996 Jun;70(6):4173-8 PMID: 8648763
  28. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome.
    Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1320-4 PMID: 8577762
  29. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli.
    J Virol. 1996 Jul;70(7):4805-10 PMID: 8676512
  30. Construction of adenovirus vectors through Cre-lox recombination.
    J Virol. 1997 Mar;71(3):1842-9 PMID: 9032314
  31. A high-efficiency Cre/loxP-based system for construction of adenoviral vectors.
    Hum Gene Ther. 1999 Nov 1;10(16):2667-72 PMID: 10566894
  32. An enhancer element is located 340 base pairs upstream from the adenovirus-2 E1A capsite.
    Nucleic Acids Res. 1983 Dec 20;11(24):8747-60 PMID: 6324099
  33. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses.
    J Virol. 1995 Apr;69(4):2004-15 PMID: 7884845
  34. Controls of RNA splicing and termination in the major late adenovirus transcription unit.
    Nature. 1981 Jul 30;292(5822):420-6 PMID: 7254339
  35. Reduction of serum cholesterol in Watanabe rabbits by xenogeneic hepatocellular transplantation.
    Nat Med. 1997 Jan;3(1):48-53 PMID: 8986740
  36. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy.
    Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11377-82 PMID: 9736744
  37. The adenovirus type 5 E1A enhancer contains two functionally distinct domains: one is specific for E1A and the other modulates all early units in cis.
    Cell. 1986 Apr 25;45(2):229-36 PMID: 2938742
  38. Evolutionary duplication of a hepatic control region in the human apolipoprotein E gene locus. Identification of a second region that confers high level and liver-specific expression of the human apolipoprotein E gene in transgenic mice.
    J Biol Chem. 1995 Nov 3;270(44):26278-81 PMID: 7592836
  39. Transfected DNA is mutated in monkey, mouse, and human cells.
    Mol Cell Biol. 1984 Oct;4(10):1951-60 PMID: 6095032
  40. Efficient manipulation of the human adenovirus genome as an infectious yeast artificial chromosome clone.
    Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6186-90 PMID: 8016135
  41. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method.
    Hum Gene Ther. 1998 Nov 20;9(17):2577-83 PMID: 9853524
  42. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells.
    Proc Natl Acad Sci U S A. 1984 Jun;81(12):3806-10 PMID: 6328526
  43. Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants.
    Hum Gene Ther. 1995 Dec;6(12):1575-86 PMID: 8664382
  44. Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector.
    Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):3854-8 PMID: 7731995
  45. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver.
    Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6196-200 PMID: 8016137
  46. Enhancement of transgene expression by cotransfection of oriP plasmid with EBNA-1 expression vector.
    Hum Gene Ther. 2000 Feb 10;11(3):471-9 PMID: 10697121
  47. Stable transduction of actively dividing cells via a novel adenoviral/episomal vector.
    Mol Ther. 2000 Apr;1(4):314-22 PMID: 10933949
  48. Characteristics of a human cell line transformed by DNA from human adenovirus type 5.
    J Gen Virol. 1977 Jul;36(1):59-74 PMID: 886304
  49. NF-IL6, a member of the C/EBP family, regulates E1A-responsive promoters in the absence of E1A.
    J Virol. 1992 Feb;66(2):1021-30 PMID: 1309887
  50. Gene therapy using adenoviral vectors.
    Curr Opin Biotechnol. 1994 Dec;5(6):617-25 PMID: 7765745
  51. Recombination and deletion of sequences in shuttle vector plasmids in mammalian cells.
    Mol Cell Biol. 1985 Sep;5(9):2265-71 PMID: 3869955
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
2000-12-00
Pages
11296-303
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC113234
Subset
IM
Grants
NHLBI NIH HHS · HL53694 · United States
NHLBI NIH HHS · HL45098 · United States
NHLBI NIH HHS · R01 HL045098 · United States
NIAID NIH HHS · F32 AI010059 · United States
NIAID NIH HHS · F32 AI10059 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com